Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.55 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.47 |
| ▸ | TOP1 | P11387 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920063 | 0.90 | MAOB (0.51) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL20767500 | 0.89 | MAOB (0.56) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL7739183 | 0.85 | MAOB (0.56) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL8327914 | 0.84 | MAOA (0.61) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL30663841 | 0.83 | MAOB (0.56) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL498282 | 0.83 | MAOB (0.56) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL3370062 | 0.82 | MAOB (0.52) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL955846 | 0.81 | MAOB (0.54) | MAOBMAOAALOX5NPC1RAB9A | |
| SCHEMBL435353 | 0.81 | POLB (0.67) | MAOBMAOAALOX5ERN1POLB | |
| SCHEMBL865350 | 0.81 | MAOA (0.58) | MAOBMAOAALOX5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| CN-103998432-A | Bicyclic compounds | TAKEDA PHARMACEUTICAL | 2014-08-20 | — | — | CN | disclosed |
| EP-1537091-B1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | HOFFMANN LA ROCHE (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-7767716-B2 | Acyl hydrazines as kinase inhibitors, in particular for SGK | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767716-B2 | Acyl hydrazines as kinase inhibitors, in particular for SGK | MERCK PATENT GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| CN-1711084-B | Substituted 4-alkoxyoxazol derivatives as PPAR agonists | HOFFMANN LA ROCHE | 2010-04-28 | — | — | CN | disclosed |
| CN-100475810-C | Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists | HOFFMANN LA ROCHE (CH) | 2009-04-08 | — | — | CN | disclosed |
| CN-101374800-A | Mandelic hydrazides | MERCK PATENT GMBH (DE) | 2009-02-25 | — | — | CN | disclosed |
| EP-1572203-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| EP-1551814-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040157898-A1 | Novel substituted oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-12 | — | — | US | disclosed |
| US-20040116487-A1 | Novel oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004041275-A1 | SUBSTITUTED 4-ALKOXYOXAZOL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004031162-A1 | CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157898-A1 | Novel substituted oxazole derivatives | OXA1L, SLC5A1, GPR119 | MAOB 2146/4885MAOA 2549/4885ALOX5 1096/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MAOB 4027/4885MAOA 4312/4885ALOX5 3343/4885 |
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | MAOB 1923/4885MAOA 2534/4885ALOX5 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.